N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery

What is the current prognostic evidence?

Anita Malhotra, Harish Ramakrishna

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

As millions of surgical procedures are performed worldwide on an aging population with multiple comorbidities, accurate and simple perioperative risk stratification is critical. The cardiac biomarker, brain natriuretic peptide (BNP), has generated considerable interest as it is easy to obtain and appears to have powerful predictive and prognostic capabilities. BNP is currently being used to guide medical therapy for heart failure and has been added to several algorithms for perioperative risk stratification. This review examines the current evidence for the use of BNP in the perioperative period in patients who are at high.cardiovascular risk for noncardiac surgery. In addition, we examined the use of BNP in patients with pulmonary embolism and left ventricular assist devices. The available data strongly suggest that the addition of BNP to perioperative risk calculators is beneficial; however, whether this determination of risk will impact outcomes, remains to be seen.

Original languageEnglish (US)
Pages (from-to)314-320
Number of pages7
JournalAnnals of Cardiac Anaesthesia
Volume19
Issue number2
DOIs
StatePublished - Apr 1 2016

Fingerprint

Brain Natriuretic Peptide
Perioperative Period
Heart-Assist Devices
Pulmonary Embolism
Comorbidity
Heart Failure
Biomarkers
Population

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine

Cite this

@article{1fb81d83f5f04118a08495f7f97ab081,
title = "N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery: What is the current prognostic evidence?",
abstract = "As millions of surgical procedures are performed worldwide on an aging population with multiple comorbidities, accurate and simple perioperative risk stratification is critical. The cardiac biomarker, brain natriuretic peptide (BNP), has generated considerable interest as it is easy to obtain and appears to have powerful predictive and prognostic capabilities. BNP is currently being used to guide medical therapy for heart failure and has been added to several algorithms for perioperative risk stratification. This review examines the current evidence for the use of BNP in the perioperative period in patients who are at high.cardiovascular risk for noncardiac surgery. In addition, we examined the use of BNP in patients with pulmonary embolism and left ventricular assist devices. The available data strongly suggest that the addition of BNP to perioperative risk calculators is beneficial; however, whether this determination of risk will impact outcomes, remains to be seen.",
author = "Anita Malhotra and Harish Ramakrishna",
year = "2016",
month = "4",
day = "1",
doi = "10.4103/0971-9784.179636",
language = "English (US)",
volume = "19",
pages = "314--320",
journal = "Annals of Cardiac Anaesthesia",
issn = "0971-9784",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "2",

}

N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery : What is the current prognostic evidence? / Malhotra, Anita; Ramakrishna, Harish.

In: Annals of Cardiac Anaesthesia, Vol. 19, No. 2, 01.04.2016, p. 314-320.

Research output: Contribution to journalReview article

TY - JOUR

T1 - N-terminal pro B type natriuretic peptide in high cardiovascular-risk patients for noncardiac surgery

T2 - What is the current prognostic evidence?

AU - Malhotra, Anita

AU - Ramakrishna, Harish

PY - 2016/4/1

Y1 - 2016/4/1

N2 - As millions of surgical procedures are performed worldwide on an aging population with multiple comorbidities, accurate and simple perioperative risk stratification is critical. The cardiac biomarker, brain natriuretic peptide (BNP), has generated considerable interest as it is easy to obtain and appears to have powerful predictive and prognostic capabilities. BNP is currently being used to guide medical therapy for heart failure and has been added to several algorithms for perioperative risk stratification. This review examines the current evidence for the use of BNP in the perioperative period in patients who are at high.cardiovascular risk for noncardiac surgery. In addition, we examined the use of BNP in patients with pulmonary embolism and left ventricular assist devices. The available data strongly suggest that the addition of BNP to perioperative risk calculators is beneficial; however, whether this determination of risk will impact outcomes, remains to be seen.

AB - As millions of surgical procedures are performed worldwide on an aging population with multiple comorbidities, accurate and simple perioperative risk stratification is critical. The cardiac biomarker, brain natriuretic peptide (BNP), has generated considerable interest as it is easy to obtain and appears to have powerful predictive and prognostic capabilities. BNP is currently being used to guide medical therapy for heart failure and has been added to several algorithms for perioperative risk stratification. This review examines the current evidence for the use of BNP in the perioperative period in patients who are at high.cardiovascular risk for noncardiac surgery. In addition, we examined the use of BNP in patients with pulmonary embolism and left ventricular assist devices. The available data strongly suggest that the addition of BNP to perioperative risk calculators is beneficial; however, whether this determination of risk will impact outcomes, remains to be seen.

UR - http://www.scopus.com/inward/record.url?scp=84964861975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964861975&partnerID=8YFLogxK

U2 - 10.4103/0971-9784.179636

DO - 10.4103/0971-9784.179636

M3 - Review article

VL - 19

SP - 314

EP - 320

JO - Annals of Cardiac Anaesthesia

JF - Annals of Cardiac Anaesthesia

SN - 0971-9784

IS - 2

ER -